



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_64130
Title of the Manuscript:	Survival and Biomarkers of COVID-19 Patients Treated with remdesivir and Favipiravir in ICU during the Peak of Pandemic: A Single Center Study in Bangladesh
Type of the Article	Original Research Article

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/journal/10/editorial-policy> )

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	The manuscript presents an important study on a possible therapy for COVID-19. Although the authors concluded that the data itself, in relation to the proposed drugs are inconclusive, there is a good possibility of exploring the data of the biomarkers used as parameters for the study. However, these data are not presented in a comfortable way for viewing and understanding the results. A list of biomarkers is cited throughout the text and in the discussion a new marker was brought before not informed (LMR) and only a brief description of the analysis of the statistical data of the biomarkers analysis is cited but not presented, such as the ROC curve. All references are very current and support the study. The authors indicate that the protocol of the study was approved by the institutional ethics board of Holy Family Red Crescent Medical College Hospital, but the number of the protocol was not informed.	
<b>Minor</b> REVISION comments	Spelling correction along the text. In many times errors are founded. The data (or some data like d-Dimer, CRP, NLR, Platelet values) on Table- 2: Prognostic biomarkers of patients treated with remdesevir and favipiravir in ICU - could be presented in graphs, with standard error bars. The statistical analysis could be presented, like the ROC curve cited, the t-test was presented, but the P value was commented, the number format of the statistical values could be minor (like 0.000), The abbreviations should be identified on the first time they appear on text.	
<b>Optional/General</b> comments	The manuscript is an important contribution for the pandemic of COVID-19.	



[SDI Review Form 1.6](#)

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Camila de Melo Accardo</b>
Department, University & Country	<b>Centro Universitário das Américas – FAM, Brazil</b>